Navigation Links
Trubion Pharmaceuticals Inc. Reports Third Quarter and Nine Months 2007 Financial Results
Date:11/12/2007

milestones and reimbursements earned through the company's Wyeth

collaboration

-- Total operating expenses - $55 million to $60 million

-- Operating cash requirements - $28 million to $32 million

Conference Call Details

Trubion will host a conference call and webcast to discuss its third quarter 2007 financial results. The call will be held today at 2 p.m. Pacific Time; 5 p.m. Eastern Time. The live event will be available from Trubion's Web site at http://investors.trubion.com/events.cfm, or by calling 1-888-208-1386 or 913-981-5593. A replay of the discussion will be available beginning later today from Trubion's Web site or by calling 1-888-203-1112 or 1-719-457-0820, and entering 4262106. The webcast replay will be available in the events section of Trubion's Web site.

About Trubion

Trubion is a biopharmaceutical company creating a pipeline of product candidates to treat autoimmune disease and cancer. The company's product candidates are novel proteins known as single-chain polypeptides and are designed using its SMIP custom drug assembly technology. In less than 24 months, the company designed, developed and submitted to the FDA an Investigational New Drug (IND) application for its lead product candidate, TRU-015, which has completed a Phase IIb clinical trial for the treatment of rheumatoid arthritis. In December 2005, the company entered into a collaboration agreement with Wyeth for the development and worldwide commercialization of certain therapeutics, including TRU-015. In addition, Trubion's TRU-016 program targets CD37, an antigen present on B cells, for the treatment of non-Hodgkin's lymphoma and chronic lymphocytic leukemia. The company filed an IND for TRU-016 in the fourth quarter of 2007. Trubion currently retains all development and commercialization rights for the TRU-016 program. For additional information visit

SOURCE Trubion Pharmaceuticals Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related biology technology :

1. Trubion Pharmaceuticals to Present at Upcoming Investor Conferences
2. Trubion Pharmaceuticals Announces Upcoming Presentations at American College of Rheumatology Annual Scientific Meeting
3. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
4. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
7. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
8. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
9. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
10. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
11. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/14/2013)... (PRWEB) June 14, 2013 The Pittcon ... Pittcon 2014, which will be held March 3-6, 2014, ... in Chicago, Illinois. The cost per booth after July ... in the first round of booth assignments should have ... floor placements will begin August 2013. , Pittcon attracts ...
(Date:6/14/2013)... June 14, 2013  The Pittsburgh Life Sciences Greenhouse ... of investment that were necessitated by delays in portfolio ... climate and the uncertainty of state funding. PLSG ... "As the region,s only pure life sciences investment firm, ... the PLSG Board of Directors, were necessary to protect ...
(Date:6/14/2013)... (PRWEB) June 14, 2013 Smart Consulting ... to provide consultation and staff augmentation services that helps ... compliance. The Smart Consulting Group / Catalyst Group alliance ... good manufacturing practices and superior quality ... an FDA compliant manufacturing process is essential for all ...
(Date:6/13/2013)... (PRWEB) June 13, 2013 University ... announced today the launch of a new medical ... patients with myelodysplastic syndromes. This interactive online program ... offers over 50 patient cases, as well as ... myelodysplastic syndromes, the most frequent malignant stem cell ...
Breaking Biology Technology:Pittcon 2014 Now Accepting Booth Space Reservations 2Pittsburgh Life Sciences Greenhouse Makes Significant Reductions Due to Uncertain Funding 2Smart Consulting Group and The Catalyst Group Form Alliance to Supply Quality Compliance Consulting Services For the Pharmaceutical Industry 2New Medical Education Program Online Helps Physicians to Make The Diagnosis of Myelodysplastic Syndrome (MDS) 2New Medical Education Program Online Helps Physicians to Make The Diagnosis of Myelodysplastic Syndrome (MDS) 3
... Graduate Institute,(KGI) in collaboration with City of Hope, ... launch of its new Certificate in Bioscience,Management program ... funding to allow a limited number of City ... scholarships that will cover tuition., "KGI has ...
... ALTO, Calif., Aug. 14 CV Therapeutics,Inc. (Nasdaq: ... from the,European Medicines Agency (EMEA) for the brand name ... announced that the EMEA had granted,marketing authorization for ranolazine ... brand name Latixa., "Securing approval for the Ranexa ...
... Eric P. Loukas, Industry Veteran, Named as CEO ... Co-Founder, Named as President and COO, ALTAMONTE SPRINGS, ... specialty biotechnology company focused on,in-licensing and commercialization of niche ... as Chief Executive Officer,effective August 12, 2008. Current President, ...
Cached Biology Technology:City of Hope Helps KGI Launch New Management Training Program for Scientists 2City of Hope Helps KGI Launch New Management Training Program for Scientists 3CV Therapeutics Receives European Approval for the Brand Name Ranexa(R) 2Milestone Biosciences, LLC Further Strengthens Executive Management Team 2
(Date:6/17/2013)... by fungi, bacteria, and algae, is a common component ... used in the medical field it,s approved by ... fluids and used during surgery as a substance that ... other drugs. , Now Profs. Ehud Gazit and Daniel ... and Biotechnology and the Sagol School of Neuroscience, along ...
(Date:6/17/2013)... will be the topics under discussion during the ... the third consecutive year, this will be a ... experiences among members of Academy, Business, Educators, Entrepreneurs, ... speakers: Elisa Martn Garijo (IBM South Europe), Chris ... Mary O,Donovan (Hovione), among others. E3 Forum - ...
(Date:6/17/2013)... available in French . ... older mice with Alzheimer,s disease can be reversed with treatment. ... Hospital - The Neuro, at McGill University and at Universit ... receptor in the brain of mice with advanced Alzheimer,s disease ... the Journal of Neuroinflammation in May, also suggest ...
Breaking Biology News(10 mins):Artificial sweetener a potential treatment for Parkinson's disease 2'E3 Forum -- Education, Employment & Entrepreneurship on a Global context' 2Blocking overactive receptor in Alzheimer's recovers memory loss and more 2
... Gasterosteus aculeatus , is one of the most thoroughly ... particularly useful model for understanding variation in physiology, behavior, ... in the wild. On biological levels from molecular ... with the population level, it has proven far more ...
... a little gooey, but it,s not turning mums, brains into ... University. The study conducted by the Centre for ... fears mothers may have that pregnancy affects their cognitive functions, ... findings have been released as part of Mental Health Week, ...
... ability to respond? Biodiversity in a Warmer World, published ... Science , illustrates that cross-disciplinary research fostered by ... this urgent debate. , As an extremely diverse region ... the most to lose as a result of global ...
Cached Biology News:Fitness in a changing world 2Fitness in a changing world 3Pregnancy not turning minds to mush: Study 2Smithsonian perspective: Biodiversity in a warmer world 2
... Select Tissue Arrays are intended for laboratory ... were fixed in neutral buffered formalin and ... diagnosis was performed by certified pathologists. ... blocks and relocated into a new recipient ...
... analysis standard is a lyophilized mixture ... alcohol; molecular weights range from 152 ... for use with the Aminex HPX-87C ... for column testing or semiquantitative determination. ...
The Odyssey Infrared Imaging System is a complete family of products that includes the Odyssey Imager, IRDye labeling reagents and Odyssey software for scan control and data analysis....
... The kit was tested on rat tissue ... a yeast ( S. cerevisae ) extract. It ... rat tissues and cell lines. Application: A simple ... sub-cellular fractions based on the detection of the ...
Biology Products: